Antimicrobial resistance in Neisseria gonorrhoeae compromises the treatment of gonorrhoea globally.1,2 After the reports of the first gonococcal strains with high-level resistance to ceftriaxone, the last remaining option for empirical gonorrhoea monotherapy, dual antimicrobial therapy (mainly ceftriaxone plus azithromycin) was implemented as the first-line treatment for uncomplicated gonorrhoea in many countries.2–7 Azithromycin resistance is described in many countries, which might threaten this dual therapy in the longer term.
Original Article: [Comment] Dual antimicrobial therapy for gonorrhoea: what is the role of azithromycin?